Dual Epitope Anti-BCMA CAR-T Cells

Products from BPS Bioscience require a minimum order value above 400€

Application: Positive control in anti-BCMA CAR-T development.Screen modulators of anti-BCMA CAR-T driven cytotoxicity.Design and optimize co-culture cytotoxicity assays.

Background: BCMA (B-cell maturation antigen), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF (tumor necrosis factor) receptor superfamily that recognizes BAFF (B-cell activating factor). BCMA is preferentially expressed in mature B lymphocytes and in Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in nonmalignant tissue but almost universal expression on MM cells. BCMA CAR-Ts are primary T cells engineered by lentiviral transduction to express a fully human-specific BCMA-CAR. CAR-T cells targeting BCMA have shown clinical anti-MM activity, and in 2022, the FDA granted authorization to use LCAR-B38M CAR-T Cell immunotherapy in MM. Active research into the development of BCMA targeting CARs for the treatment of several oncogenic disorders is ongoing, and represents a promising therapeutic avenue in cancer therapy.

Description: The Dual Epitope Anti-BCMA CAR-T Cells are generated via high-titer lentiviral transduction of human primary CD4⁺ and CD8⁺ T cells with the SIN Anti-BCMA CAR Lentivirus (VHH1/VHH2 ScFv-CD8-4-1BB-CD3ζ) (#78783). These ready-to use CAR (chimeric antigen receptor)-T cells express an anti-BCMA CAR consisting of a ScFv (single-chain variable fragment) that recognizes two BCMA epitopes (VHH1 and VHH2) linked to a CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains.These CAR-T cells have been validated by flow cytometry (to determine the CAR expression) and in co-culture cytotoxicity assays.

Host Cell Line: N/A

Mycoplasma Testing: The cells have been screened to confirm the absence of Mycoplasma species.

Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.

Supplied As: Each vial contains ˃1 x 10⁶ cells in 1 ml of CryoStor® CS10 (Stemcell Technologies #07942)

Warnings: Avoid freeze/thaw cycles.Donors have been screened and determined negative for:Hepatitis B (anti-HBc EIA, HBsAg EIA)Hepatitis C (anti-HCV EIA)Human Immunodeficiency Virus (HIV-1/HIV-2 plus O)Human T-Lymphotropic Virus (HTLV-I/II)HIV-1/HCV/HBVWest Nile VirusTrypanasoma cruziNote: Testing cannot guarantee that any sample is completely virus-free. These cells should be treated as potentially infectious and appropriate Biological Safety Level 2 (BSL-2) precautions should be used.

Biosafety Level: BSL-1

References: Ghosh A., et al., 2017 Leuk Lymphoma. 6:1-12
Sanchez E., et al., 2018 Expert Rev Mol Diagn. 7:1-11.
Sohail A., et al., 2018 Immunotherapy. 10(4):265-282.
Sidaway P., et al., 2016 Nat Rev Clin Oncol. 13(9):530.

• Artikelnummer: BPS78790-1
• Hersteller: BPS Bioscience
• Hersteller Artikelnummer: 78790-1
• Verpackungseinheit: 1 vial
• Mengeneinheit: STK
• Wirt: Human